Beyond the role of PARP1 in oncology, emerging research has indicated its potential as a therapeutic target against Alzheimer's disease and Parkinson's disease, which have been shown to upregulate PARP1 and lead to neuroinflammation, mitochondrial dysfunction, and autophagy dysregulation [24, 25]. This evidence concerns the gene PARP1 and Alzheimer disease.